Skip to main content
See every side of every news story
Published • loading... • Updated

Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy

Researchers found the elevated preterm-birth risk was confined to women using semaglutide or liraglutide for diabetes, not weight loss.

Summary by Science Daily
A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs' safety during pregnancy remains uncertain.

4 Articles

A study has found that even if women used Wigovi or Ozempic without knowing they were pregnant, the risk of premature birth or other pregnancy complications did not significantly increase if the goal was weight loss. Conversely, the risk of premature birth was found to increase in women prescribed the same class of drugs for diabetes treatment. According to Science Daily on the 13th (local time), researchers at the Department of Obstetrics and…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MSNBCTV NEWS broke the news on Friday, November 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal